Binding and functional selectivity of himbacine for cloned and neuronal muscarinic receptors

JH Miller, PJ Aagaard, VA Gibson and M McKinney

Department of Pharmacology, Mayo Clinic Jacksonville, Florida.

The binding potencies for the putative M2-selective antagonist himbacine were determined in radioligand binding and in functional response assays in neuronal tissue and Chinese hamster ovary cells containing transfected muscarinic receptors. Himbacine was shown to bind to all five cloned muscarinic receptor subtypes in the order of potencies: hM2 = hM4 > hM3 > hM1 > hM5 (Kd values were 4, 7, 59, 83 and 296 nM, respectively). Himbacine was shown to bind to M2 receptors in rat heart and brain stem with Kd values of 6.9 and 4.6 nM, respectively. In rat brain tissues with complex mixtures of muscarinic receptors, and using the radioligand [3H] +/- -5,11-dihydro-11-([(2-(2- [(dipropylamino)methyl]-1- peperidinyl)ethyl)amino]carbonyl)-6H- pyrido(2,3-b)(1,4)benzodiazep ine-6-one to demarcate M2 and M4 receptors, himbacine was shown to bind to 80% of cortical or striatal receptors with Kd values of 4.5 and 3.8 nM, respectively, consistent with the involvement of M2 and/or M4 receptors in both these brain regions. Himbacine was a potent blocker of oxotremorine-M-mediated cyclic AMP inhibition in rat striatum (4.4 nM) and in N1E-115 neuroblastoma cells (10.6 nM), responses mediated by M4 receptors. Himbacine also reversed oxotremorine-M-mediated inhibition of evoked acetylcholine release from hippocampal tissue with a Kd value of 8.6 nM, a value consistent with the involvement of M2 or M4 receptors. At the cortical postsynaptic muscarinic receptors involved with phosphoinositide turnover (putative M1 and M3 receptors), himbacine was 21-fold less potent. Himbacine appears to be a potent muscarinic antagonist that displays selectivity for M2 or M4 receptors, as compared to M1 or M3 receptors.(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 263, Issue 2, pp. 663-667, 11/01/1992
Copyright © 1992 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				H.-M. Zhang, H.-Y. Zhou, S.-R. Chen, D. Gautam, J. Wess, and H.-L. Pan Control of Glycinergic Input to Spinal Dorsal Horn Neurons by Distinct Muscarinic Receptor Subtypes Revealed Using Knockout Mice J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 963 - 971. [Abstract] [Full Text] [PDF]

				H.-M. Zhang, S.-R. Chen, and H.-L. Pan Regulation of Glutamate Release From Primary Afferents and Interneurons in the Spinal Cord by Muscarinic Receptor Subtypes J Neurophysiol, January 1, 2007; 97(1): 102 - 109. [Abstract] [Full Text] [PDF]

				H.-M. Zhang, S.-R. Chen, M. Matsui, D. Gautam, J. Wess, and H.-L. Pan Opposing Functions of Spinal M2, M3, and M4 Receptor Subtypes in Regulation of GABAergic Inputs to Dorsal Horn Neurons Revealed by Muscarinic Receptor Knockout Mice Mol. Pharmacol., March 1, 2006; 69(3): 1048 - 1055. [Abstract] [Full Text] [PDF]

				X.-L. Wang, H.-M. Zhang, D.-P. Li, S.-R. Chen, and H.-L. Pan Dynamic regulation of glycinergic input to spinal dorsal horn neurones by muscarinic receptor subtypes in rats J. Physiol., March 1, 2006; 571(2): 403 - 413. [Abstract] [Full Text] [PDF]

				H.-M. Zhang, D.-P. Li, S.-R. Chen, and H.-L. Pan M2, M3, and M4 Receptor Subtypes Contribute to Muscarinic Potentiation of GABAergic Inputs to Spinal Dorsal Horn Neurons J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 697 - 704. [Abstract] [Full Text] [PDF]

				J. L. Ellis, D. Harman, J. Gonzalez, M. L. Spera, R. Liu, T. Y. Shen, D. M. Wypij, and F. Zuo Development of Muscarinic Analgesics Derived from Epibatidine: Role of the M4 Receptor Subtype J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 1143 - 1150. [Abstract] [Full Text]